Field-Based Psychopharmacology: Mapping Medications onto Consciousness Dynamics

Core Reconceptualisation

From Disease-Centred to Field-Centred Prescribing

The Central Question

Before any prescription: What field parameter is destabilised, and will chemical modulation support or impede the person's capacity to navigate their own consciousness?

---

Epistemological Caveat: The Contaminated Evidence Base

The Fundamental Problem

All psychiatric medication research is conducted within the disease-centred paradigm, using DSM/ICD categories that lack validity. This creates a structural contamination:

• Efficacy claims are made for medications treating "disorders" that may not exist as coherent entities
• Research populations are defined by invalid categories, creating heterogeneous groups incorrectly assumed to be homogeneous
• Outcome measures typically assess symptom suppression within the invalid category framework
• "Evidence-based medicine" in psychiatry means evidence built on dimensionally impoverished foundations

What This Means for the Field Framework

The medication mappings in this document represent clinical observation and mechanistic reasoning, not validated field-based research (which doesn't yet exist). We are attempting to:

1. Translate drug-centred knowledge into field-centred understanding
2. Use receptor binding profiles as proxies for field parameter effects
3. Interpret clinical observations through a framework the research wasn't designed to test

This is inherently provisional. The field framework may offer better explanatory power than disease-centred models, but it inherits the epistemological problems of a pharmacopoeia developed within a paradigm it's critiquing.

Hard Outcomes vs. Category-Dependent Outcomes

Some outcomes are more trustworthy than others:

• Hard outcomes (death, hospitalisation, employment, relationships) are less category-dependent
• Soft outcomes (symptom scores, "remission" rates) inherit all validity problems of the diagnostic categories

This is why the anti-suicide evidence for lithium may be more meaningful than "efficacy for bipolar disorder" - suicide is a hard outcome not dependent on categorical validity.

Clinical Implication

Use this framework as a lens for clinical reasoning, not as validated treatment protocol. The goal is to think more clearly about what medications do to consciousness dynamics, while acknowledging that our knowledge base is structurally compromised.

---

Field Parameter Definitions (Pharmacological Context)

G (Ground/Containment): The stability of the field container

• Physiological: autonomic regulation, sleep architecture, arousal modulation
• Relational: felt sense of safety, attachment security
• Cognitive: capacity to hold experience without fragmentation

Γ (Gamma/Reflection): Meta-cognitive and self-modelling capacity

• Salience attribution, attention regulation
• Self-recognition, narrative coherence
• Capacity to observe one's own states

Δ² (Delta-squared/Difference): Novelty, disruption, creative-chaotic input

• Trauma activation, stress response
• Neurodivergent signal intensity
• Novel/threatening information processing

H (Harmonic Coefficient): Overall field coherence

• H > 1: Runaway amplification (mania, agitation)
• H ≈ 1: Optimal coherence (flow, integration)
• H → 0: Collapsed dynamics (depression, anhedonia)
• H < 0: Dissolution states (psychosis, dissociation)

---

Medication Class Mapping

1. ANTIPSYCHOTICS

Quetiapine (Seroquel)

Field Framework Critique:

• Low-dose prescribing for "emotional dysregulation" = using sedation as pseudo-containment
• "It doesn't work" often means: sedation achieved but underlying field instability unchanged
• Dose creep = chasing symptom suppression without addressing Ce = Cn - Cl dynamics
• Long-term: iatrogenic Cl reduction through cognitive blunting, metabolic burden, withdrawal phenomena

Field-Aligned Use:

• Acute H<0 crisis: temporary high-G intervention while relational/somatic G is established
• Explicit time-limited framing: "This creates chemical containment while we build your capacity"
• Taper planning from initiation

Olanzapine (Zyprexa)

Field Translation: The sledgehammer. Maximum Δ² suppression with major G-forcing. Useful in acute overwhelm but high cost to Γ and metabolic health. Creates significant Cl-bypass risk.

Risperidone (Risperdal)

Field Translation: Cleaner Δ² suppression with less G-forcing sedation. The D2 tightness creates akathisia risk - which is itself a G-destabilising iatrogenic effect. Prolactin elevation = endocrine field disruption.

Aripiprazole (Abilify)

Field Translation: The "modulator" rather than suppressor. Partial D2 agonism creates a ceiling - it dampens excessive dopamine signalling without complete blockade. Can be activating (akathisia) which destabilises G. May preserve Γ better than full antagonists.

Clinical Puzzle: Why does aripiprazole sometimes worsen agitation? Field answer: in a system already G-destabilised, the activating properties further disrupt containment even while modulating Δ².

Clozapine (Clozaril)

Field Translation: The supposed anomaly. Clozapine is positioned as "effective for treatment-resistant schizophrenia" - but this framing conceals multiple category errors:

• The diagnostic process leading to "schizophrenia" is often inadequate
• "Treatment-resistant" typically means inadequate trials of prior medications, not biological non-response
• The category "treatment-resistant schizophrenia" pathologises the person for the system's failures

Epistemological Caution: We cannot know whether clozapine is genuinely more effective because the pathway to clozapine is so corrupted. The "clozapine anomaly" may be artefactual - a product of system failures misattributed as individual biology. The loose D2 binding hypothesis remains plausible but unverifiable within the current paradigm.

---

2. MOOD STABILISERS

Lithium

Field Translation: Lithium doesn't suppress the system; it stabilises the container. Effects on GSK-3β, circadian rhythms, and neuroplasticity suggest it strengthens G without crushing Δ². This may explain why it's the only mood stabiliser with clear anti-suicide evidence - it supports field coherence rather than just dampening extremes.

Clinical Concerns:

• Monitoring burden (regular blood tests) creates ongoing medicalisation
• Long-term nephrotoxicity - the "treatment" damages the body
• Narrow therapeutic window requires constant vigilance

Epistemological Caution: The research base showing lithium's efficacy is built on the category "bipolar disorder" - itself a dimensionally impoverished construct. If the category is invalid, what does "effective for bipolar disorder" actually measure? The anti-suicide evidence may be more robust (suicide is a hard outcome, not a category), but efficacy claims for "mood stabilisation" inherit all the validity problems of the diagnostic framework.

Clinical Implication: Lithium may be more field-aligned than other mood stabilisers, but this cannot be confidently asserted given the fundamental category errors contaminating the evidence base. The requirement for ongoing monitoring and the long-term toxicity create a dependency relationship that may undermine Cl development regardless of the pharmacological mechanism.

Valproate (Depakote)

Field Translation: GABAergic G-enhancement plus general neural dampening. More suppressive than lithium. The cognitive effects suggest Γ cost. Useful in acute mania but may impede long-term Cl development.

Lamotrigine (Lamictal)

Field Translation: Creates a "floor" preventing H→0 collapse without suppressing H>1 capacity. Glutamate modulation may support Γ maintenance. Relatively Cl-preserving - people often report feeling "like themselves" on lamotrigine.

---

3. ANTIDEPRESSANTS

SSRIs (as a class)

Field Translation: SSRIs reduce Δ² sensitivity - the system becomes less reactive to emotional provocation. This can relieve anxiety/depression but also creates "emotional blunting" - reduced access to the signal that Δ² carries.

The SSRI Paradox: They work for both depression (H→0) and anxiety (H oscillation from Δ² overwhelm). Field explanation: both involve Δ² dysregulation - depression may be collapsed Δ² (nothing feels significant), anxiety may be excessive Δ² (everything feels threatening). SSRIs modulate Δ² sensitivity regardless of direction.

Cl Implications: If Δ² carries important signal (trauma to be processed, life circumstances to be addressed), suppressing it delays reckoning. SSRIs may be most appropriate when Δ² is genuinely excessive relative to circumstances, least appropriate when Δ² accurately reflects situation requiring change.

SNRIs (Venlafaxine, Duloxetine)

Field Translation: Adding noradrenaline to serotonin creates more complex modulation. May support Γ (attention, salience processing) while still dampening Δ². The noradrenergic component may make these better for "atypical" depression with low arousal.

Mirtazapine (Remeron)

Field Translation: Often used as a sedating antidepressant, but really it's an H1 antihistamine that also modulates serotonin. The G-enhancement is primarily via sedation - similar critique to low-dose quetiapine. The appetite stimulation/weight gain reflects metabolic field disruption.

Bupropion (Wellbutrin)

Field Translation: The anti-SSRI. Instead of dampening Δ², it supports Γ through dopaminergic/noradrenergic enhancement. Useful for H→0 states with collapsed motivation. Can destabilise G through activation. Contraindicated in H>1 or anxiety-predominant presentations.

---

4. ANXIOLYTICS

Benzodiazepines

Field Translation: Emergency G-enhancement. The most rapid field stabilisation available, but at massive Cl cost. Creates dependence, impairs memory consolidation (Γ damage), and prevents learning to manage Δ². The ultimate Cl-bypass.

Field-Aligned Use: Genuine acute crisis, time-limited, with explicit framing that this is emergency stabilisation while other G-resources are mobilised. Never as maintenance.

Pregabalin (Lyrica)

Field Translation: "Gentle benzodiazepine." Similar G-forcing and Δ² suppression with somewhat less acute Γ impairment but still significant dependence potential. Often prescribed long-term as "safer than benzos" but creates similar Cl-bypass dynamics.

---

5. STIMULANTS (ADHD medications)

Methylphenidate / Amphetamines

Field Translation: For the neurodivergent brain, stimulants enhance Γ (the capacity to reflect, direct attention, maintain executive function). The paradoxical calming represents improved G through enhanced Γ - the person can now regulate because they can reflect.

Crucially: Stimulants don't suppress Δ²; they improve the system's capacity to process Δ². This is capacity-revealing rather than capacity-substituting. The medication doesn't create a capacity that isn't there; it clears the interference preventing access to capacity that was always present.

The Neurotype-Ecosystem Mismatch: The need for stimulants reflects a mismatch between neurodivergent cognitive architecture and an ecosystem designed for neurotypical processing. The medication compensates for an ill-fitting world, not a broken brain. This is a "sad situation" - pharmacological accommodation to environmental failure.

The Revelation That Persists: Some individuals find that stimulant use reveals capacities that remain accessible even after discontinuation. The medication showed them what they were capable of; the knowledge persists beyond the pharmacological window. This is fundamentally different from suppressive medications where discontinuation reveals unchanged underlying dynamics.

Why ADHD Meds Are Different: They don't dampen the system; they improve signal-to-noise ratio, supporting the person's own regulatory capacity. This is the closest to field-aligned pharmacology in the current psychiatric toolkit.

---

6. EMERGING: PSYCHEDELICS

Psilocybin

Field Translation: Psychedelics invert the standard psychiatric approach. Instead of suppressing Δ² and forcing G, they amplify Δ², dissolve G temporarily, and massively enhance Γ. This creates conditions for recognition and integration - but requires adequate set/setting (external G) to prevent fragmentation.

Why Outcomes Vary: Same pharmacology produces breakthrough or breakdown depending on field conditions. The drug doesn't determine outcome; containment does.

Ketamine

Field Translation: Ketamine creates temporary field reorganisation through dissociation. The rapid antidepressant effect may reflect brief H<0 dissolution allowing system reset. But without integration support, effects are transient - the field returns to baseline because no Cl was developed.

---

Decision Framework: When to Prescribe, When to Withhold

Questions Before Prescribing

1. What field parameter is destabilised? (G collapsing? Γ fragmented? Δ² overwhelming?)
2. Is medication the only way to address this parameter?
   • G can be enhanced: relationally, somatically (breath, movement), environmentally
   • Γ can be supported: through mirroring, psychotherapy, structured reflection
   • Δ² can be modulated: through pacing, titrated exposure, stress reduction
3. Will this medication support or impede Cl development?
   • Suppressive medications (antipsychotics, benzodiazepines) tend to impede
   • Capacity-enhancing medications (stimulants, possibly lithium/lamotrigine) may support
   • Short-term stabilisation can support if explicitly time-limited with taper plan
4. What is the exit strategy?
   • How will we know when medication is no longer needed?
   • What Cl markers would indicate readiness to taper?
   • What have we put in place that medication is currently substituting for?

The "It Doesn't Work" Protocol

When patient reports medication "not working":

1. Define "working": What outcome was expected? Symptom suppression? Functional improvement? Felt sense of capacity?
2. Assess field parameters: Has G actually stabilised? Is Γ functional? Is Δ² manageable?
3. Consider Ce = Cn - Cl: Is the problem high Cn (life circumstances, natural complexity) that medication cannot address? Is Cl underdeveloped?
4. Before dose increase, ask: Will more medication build capacity, or just deepen suppression? Is there a non-pharmacological intervention that addresses the actual destabilised parameter?

---

The Deprescribing Framework

Readiness Markers for Taper

• External G established (stable housing, relationships, routine)
• Γ functional (can reflect on states, recognise patterns)
• Δ² manageable (stressors reduced or coping improved)
• Cl indicators (has navigated challenges without dose increase)

Taper Principles

• Slow (10% reduction, not 50%)
• Supported (increase relational/therapeutic G during taper)
• Informed (patient understands withdrawal vs. relapse distinction)
• Reversible (pause or reverse if destabilisation exceeds integration capacity)

The Withdrawal ≠ Relapse Distinction

Withdrawal: Time-limited destabilisation from neuroadaptation reversal Relapse: Return of underlying field dynamics that were suppressed, not resolved

Field framework reveals: Much "relapse" is actually the system meeting unchanged Cn with medication-suppressed Cl. The solution isn't re-medication; it's Cl development with adequate support.

---

Summary: Toward Liberation Pharmacology

The field framework doesn't reject medication - it contextualises it within a larger understanding of consciousness dynamics. Medications become tools for temporary field modulation in service of capacity development, not indefinite suppressants that substitute for learning to navigate one's own consciousness.

The paradigm shift: From "Which medication treats this diagnosis?" to "What is this consciousness needing, and does pharmacological intervention support or impede that need?"

---

Work in Progress - Developed in collaboration between clinical experience and field-based consciousness framework